Key terms
About CDNA
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CDNA news
Apr 16
4:32pm ET
CareDx Appoints John W. Hanna as New CEO and Board Member
Apr 16
4:02pm ET
CareDx names John Hanna as new CEO
Mar 11
4:13pm ET
CareDx Enhances Board with Financial Expert Riggsbee
Mar 06
6:25am ET
CareDx Hold Rating: Balancing Modest Growth Prospects with Operational Uncertainties
Feb 29
12:53pm ET
CareDx turns positive with CMS transplant update seen as positive
Feb 29
12:33pm ET
CMS announcement positive for CareDx and Natera, says Craig-Hallum
Feb 29
12:30pm ET
CMS says transplant patients can continue to access blood tests
Feb 29
6:44am ET
Balancing Growth Prospects Against Financial Challenges: A Hold Rating for CareDx
Feb 28
4:49pm ET
CareDx Unveils Updated Financial Health and Strategy Presentation
Feb 28
4:31pm ET
CareDx sees FY24 revenue $260M-$274M, consensus $260.6M
Feb 28
4:30pm ET
CareDx reports Q4 EPS (17c), consensus (27c)
Feb 27
8:25am ET
Natera announces next phase of CareDx patent infringement litigation
Feb 26
9:07am ET
Craig-Hallum Issues a Hold Rating on CareDx (CDNA)
Jan 29
6:35am ET
H.C. Wainwright Keeps Their Hold Rating on CareDx (CDNA)
Jan 28
7:12am ET
CareDx found to have not infringed on one Natera patent, infringed on another
Jan 26
3:55pm ET
Wolfe reiterates Outperform on Natera after favorable jury decision
Jan 26
1:37pm ET
CareDx weakness attributed to ruling in patent fight
No recent press releases are available for CDNA
CDNA Financials
Key terms
Ad Feedback
CDNA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CDNA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range